Cancer

Cosmos Health Enters Development Phase for CCDL24, an Innovative Multitargeting Product for Gastrointestinal Disorders, with a Market Size Valued at Over $37.5 Billion

CHICAGO, IL / ACCESSWIRE / September 19, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified,…

1 year ago

RenovoRx Announces Presentation at Symposium on Clinical Interventional Oncology Highlighting TAMP™ for Targeted Treatment of Locally Advanced Pancreatic Cancer

Published data shows that chemotherapy delivered via TAMP with prior chemoradiation in Locally Advanced Pancreatic Cancer observed an Overall Survival…

1 year ago

Helsinn Group appoints Riccardo Carbucicchio to the Board of Directors

Helsinn Group appoints Riccardo Carbucicchio to the Board of Directors Lugano, Switzerland – September 19, 2024 – Helsinn Group (“Helsinn”), a…

1 year ago

Evaxion launches improved AI-Immunology™ platform for vaccine antigen prediction

The new version 5.0 of the AI model EDEN™ features a novel toxin antigen predictor, is trained on an expanded…

1 year ago

AIM ImmunoTech Reports Positive Preliminary Data in Phase 1b/2 Study of Ampligen and Imfinzi as a Combination Therapy for Late-Stage Pancreatic Cancer

Preliminary finding of stable disease in two out of three patients at 6 months in the first subject cohort Combination…

1 year ago

Achilles Therapeutics Announces Strategic Update

–Achilles to discontinue development of TIL-based cNeT therapy– –Cash position of $95.1 million as of June 30, 2024– –BofA Securities…

1 year ago

ITM to Present at Upcoming Radiopharmaceutical Investor Conferences in New York City

Garching / Munich, September 19, 2024 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced…

1 year ago

Basilea enters into agreement with BARDA to develop novel antifungals and antibacterials and receives initial funding

Initial funding of USD 29 million to support development of Basilea’s clinical stage first-in-class antifungals, fosmanogepix and BAL2062Multi-year Other Transaction…

1 year ago